Surgery, Crohn's disease, and the biological era: has there been an impact?
AffiliationCentre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland., Slattery.email@example.com
Antibodies, Monoclonal/*therapeutic use
Crohn Disease/drug therapy/surgery/*therapy
Digestive System Surgical Procedures/*trends
Gastrointestinal Agents/*therapeutic use
Immunologic Factors/*therapeutic use
MetadataShow full item record
CitationJ Clin Gastroenterol. 2011 Sep;45(8):691-3.
JournalJournal of clinical gastroenterology
AbstractINTRODUCTION: The management of Crohn's disease (CD) has changed considerably over the last 20 years. Immunomodulators and biological therapies now play a role in treating patients with CD, but little is known of their influence on surgical rates. AIM: To review the surgery rates for CD in an Irish university hospital over a 20-year period and to determine whether newer therapies had an impact on surgical rates. METHOD: Seven hundred twenty-two patients attending St Vincent's University Hospital, Dublin, with CD over a 20-year period (January 1986 to December 2005) were identified. The patients were divided into quartiles. Resection rates were determined in all the quartiles, at both 1 and 3 years from diagnosis. RESULTS: A decline in surgery, 3 years from diagnosis, was noted between the first quartile (72 patients, 40%) and the second quartile (58 patients, 32%; P=0.03). No significant change in surgical rates at 3 years occurred between the other 3 quartiles (32%, 30%, and 35%, respectively; P=NS). The patients who required a resection within 3 years were diagnosed at a younger age in later years. There was a similar predominance of 60% of female patients requiring surgery in all groups. The patients requiring surgery were twice as likely to be ex-smokers or current smokers in all groups. Use of infliximab, within 3 years from diagnosis, increased from 0, 0, and 16 patients (8.8%) to 40 patients (22.1%) in the last quartile. The majority of patients were treated with infliximab on an "on demand" basis. Use of infliximab earlier within the course of the disease was seen in later quartiles (ie, within 1 y of diagnosis): 0, 0, 6, and 21 patients. CONCLUSION: Despite the introduction of infliximab over the past 10 years, no demonstrable difference has been seen in the rates of patients requiring resection surgery within 3 years of diagnosis. The reasons for this are unclear, but may relate to episodic treatment, rather than regular maintenance treatment. Female patients and smokers seem to be particularly at risk of resection surgery.
- Trends in surgery for Crohn's disease in the era of infliximab.
- Authors: Jones DW, Finlayson SR
- Issue date: 2010 Aug
- Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis.
- Authors: Szamosi T, Banai J, Lakatos L, Czegledi Z, David G, Zsigmond F, Pandur T, Erdelyi Z, Gemela O, Papp M, Papp J, Lakatos PL
- Issue date: 2010 Jul
- Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates.
- Authors: Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB
- Issue date: 2010 Sep
- A 5-year prospective observational study of the outcomes of international treatment guidelines for Crohn's disease.
- Authors: Cullen G, Keegan D, Mulcahy HE, O'Donoghue DP
- Issue date: 2009 Mar
- Risk factors for initial surgery in pediatric patients with Crohn's disease.
- Authors: Gupta N, Cohen SA, Bostrom AG, Kirschner BS, Baldassano RN, Winter HS, Ferry GD, Smith T, Abramson O, Gold BD, Heyman MB
- Issue date: 2006 Apr